<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143016">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028884</url>
  </required_header>
  <id_info>
    <org_study_id>SA-307JG</org_study_id>
    <secondary_id>2013-003752-21</secondary_id>
    <nct_id>NCT02028884</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD</brief_title>
  <official_title>A Multicenter, Randomized, Addition to Baseline Treatment, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy, safety, pharmacodynamic,
      pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>up to approximately 30 months from first patient in</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>up to approximately 30 months from first patient in</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Neuromyelitis Optica (NMO)</condition>
  <condition>NMO Spectrum Disorder (NMOSD)</condition>
  <arm_group>
    <arm_group_label>SA237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous SA237</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SA237</intervention_name>
    <arm_group_label>SA237</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. NMO or NMOSD

          2. Age 12 to 74 years, inclusive at the time of informed consent.

        Exclusion Criteria

          1. Pregnancy or lactation.

          2. Evidence of other demyelinating disease or progressive multifocal leukoencephalopathy
             (PML).

          3. Known active infection (excluding fungal infections of nail beds or caries dentium)
             within 4 weeks prior to baseline.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akinori Yamada</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical trials information</last_name>
    <email>clinical-trials@chugai-pharm.co.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SA237 Clinical trial</last_name>
    <email>sa237@chugai-pharm.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Kansai region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>January 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
